BIBF 1120/Nintedanib: A New Triple Angiokinase Inhibitor-Directed Therapy in Patients With Non-Small Cell Lung Cancer

Expert Opinion on Investigational Drugs - United Kingdom
doi 10.1517/13543784.2013.812630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare

Related search

BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but Not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2013English

Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker in Vivo

Clinical Cancer Research
Cancer ResearchOncology
2010English

New Strategies in Lung Cancer: Epigenetic Therapy for Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

Recent Advances in Targeted Small-Molecule Inhibitor Therapy for Non-Small-Cell Lung Cancer-An Update

Journal of Clinical Pharmacy and Therapeutics
Pharmacology
2020English

Maintenance Therapy Improves Survival Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

Lung
PulmonaryRespiratory Medicine
2015English

Ifosfamide in Patients With Recurrent Non Small Cell Lung Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
1986English

A Novel PI3K Inhibitor iMDK Suppresses Non-Small Cell Lung Cancer Cooperatively With a MEK Inhibitor

Experimental Cell Research
Cell Biology
2015English

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy